Abstract:Ethnopharmacological relevance Transcatheter arterial chemoembolization (TACE) is recommended as the first-line therapy for unresected primary liver cancer (PLC), but only partial patients could benefit from TACE due to the serious adverse reactions. Clearing heat and resolving toxin (CHRT), one of most critical traditional Chinese medicine (TCM) therapeutic principles, has been widely used in the treatment of PLC patients especially after TACE. However, there is no enough clinical evidence to confirm the efficacy and safety of the combined therapy. Aim of the study To comprehensively evaluate the efficacy and safety of the combined CHRT-CHF with TACE in the treatment of PLC. Materials and methods 7 databases were searched from their inception until February 1, 2023. The primary outcomes included survival rate (1-, 2-year), objective response rate (ORR) and disease control rate (DCR), liver function indicators (AST, ALT), adverse reactions including fever, upper digestive tract side and myelosuppression, AFP were selected as the secondary outcomes. RevMan5.4 software was used to evaluate the quality of included studies; meta-analysis, subgroup analysis, meta-regression analysis, publication bias and trial sequential analyses (TSA) was conducted by Stata software 12.0. Results There were 40 RCTs involving 3649 patients. Patients treated with TACE plus CHRT-CHF showed significantly better 1-, 2-year survival (respectively: OR, 2.23 [1.67–2.97]; OR, 2.13 [1.56–2.92]), ORR (OR, 2.14 [1.82–2.52]), DCR (OR, 2.13 [1.73–2.62]) compared with TACE alone. There was a decreased incidence of aspartate transaminase (AST), alanine transaminase (ALT), alpha-fetoprotein (AFP) and postembolization syndrome (PES) in patients receiving the combined TACE with CHRT-CHF compared with TACE alone. Subgroup analysis found that lower proportion (20–30%) of CHRT-CHF significantly enhanced survival rate and DCR, higher proportion (≥40%) of CHRT-CHF reduced PES after TACE treatment. Conclusion The efficacy and safety of the combined CHRT-CHF with TACE were validated in this meta-analysis, the optimal proportion of CHRT-CHF in enhancing the efficacy may be 20–30%; Additionally, higher proportion (≥40%) of CHRT-CHF appears to reduce PES after TACE treatment. The potential role of combined relative proportion of CHRT-CHF with TACE should be emphasized in clinic.

Transcatheter Arterial Chemoembolization In Combination With Stereotactic Body Radiation Therapy In Primary Liver Carcinoma: A Systematic Review And Meta-Analysis

Evaluation of the Efficacy for Alternated Treatment on Primary Liver Cancer by Interventional Therapy in Combination with Fractionated Stereotactic Conformal Radiotherapy

A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer

Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization Versus Stereotactic Body Radiotherapy Alone As the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review

Radiotherapy Combined with Transcatheter Arterial Chemoembolization Versus Transcatheter Arterial Chemoembolization Alone for Primary Hepatic Carcinoma:A Meta-Analysis

Effect of TACE Combined with Stereotactic Body X-knife on the Patients with Hepatocellular Carcinoma

TACE Combined with Thermotherapy for Primary Hepatic Carcinoma; A Meta-Analvsis

Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Barcelona-Clinic Liver Cancer (BCLC) A Hepatocellular Carcinoma: a Meta-Analysis

The Effect of Trans Arterial Chemoembolization in the Management of Intrahepatic Cholangiocarcinoma. A Systematic Review and Meta-Analysis

The therapeutic principle of combined clearing heat and resolving toxin plus TACE on primary liver cancer: A systematic review and meta-analysis

Efficacy and Prognostic Factors of Trans-Arterial Chemoembolization Combined With Stereotactic Body Radiation Therapy for BCLC Stage B Hepatocellular Carcinoma

Effect of Yttrium-90 Microsphere Transarterial Radioembolization for Unresectable Primary Liver Cancer：a Meta-analysis

Transarterial Chemoembolization In Combination With Local Therapies For Hepatocellular Carcinoma: A Meta-Analysis

Effectiveness and Safety of TACE Combined with AHCS for Primary Hepatic Carcinomas: A Systematic Review

Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study

Efficacy combined transcatheter arterial chemoembolization(TACE)and radiotherapy for advanced primary liver cancer

Efficacy and Complications of Transarterial Chemoembolization Alone or in Combination with Different Protocols for Hepatocellular Carcinoma: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Transcatheter Arterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Versus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-analysis

[Comparison of Therapeutic Effects Between Transcatheter Arterial Chemoembolization and Transcatheter Arterial-Portal Venous Double Chemoembolization in Treatment of Moderate and Advanced Stages of Primary Liver Carcinoma].

Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis

Transcatheter Arterial Chemoembolization in Combination with Radiotherapy for Unresectable Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis.